首页> 外文期刊>Progress in Artificial Intelligence >Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis
【24h】

Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis

机译:用于治疗新型冠状病毒(Covid-19)肺炎的中药药物:系统审查和荟萃分析的议定书

获取原文
获取原文并翻译 | 示例
       

摘要

Background A new type of coronavirus, novel coronavirus (COVID-19), is causing an increasing number of cases of pneumonia and was declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China, in late December 2019, and traditional Chinese herbal medicine is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of traditional Chinese herbal medicine in COVID-19 pneumonia. Methods We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wanfang database using keywords related to COVID-19 and traditional Chinese herbal medicine. Reference lists of relevant trials and reviews will be searched. We will manually search gray literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies (XL and DZ), extract data (YL and LG), and evaluate risk of bias (YL and DZ). Data analysis will be conducted using the Review Manager software (version 5.3.5) and R software (version 3.6.1). Statistical heterogeneity will be assessed using a standard chi-square test with a significance level of P < 0.10. Biases associated with study size (e.g., publication bias) will be investigated using funnel plots, Egger's test and Begg's test, and Trim and Fill analysis. Discussion This study will provide a high-quality synthesis of the effects of traditional Chinese herbal medicine for COVID-19. The use of traditional Chinese herbal medicine for treatment or prevention of these novel viral infections affecting the pneumonia will be investigated. Systematic review registration PROSPERO registration number:
机译:背景技术新型冠状病毒新型冠状病毒(Covid-19),导致肺炎患者患者患者,并于2012年1月30日宣布世界卫生组织的国际卫生问题。该病毒首先出现在武汉,中国,2019年12月下旬,中国中草药的治疗被用来。这种系统审查和荟萃分析将评估中国中草药在Covid-19肺炎中的影响。方法我们将搜索电子数据库,包括PubMed,Embase,Cochrane中央登记册(中央),中国生物医学文献数据库(CBM),中国国家知识基础设施(CNKI),中国科技期刊数据库(VIP),以及万功使用与Covid-19和中草药相关的关键字使用关键词。将搜索相关审判和评论的参考列表。我们将手动搜索灰色文学,例如会议程序和学位论文,以及试验登记处。两个独立审阅者将屏幕研究(XL和DZ),提取数据(YL和LG),评估偏置的风险(YL和DZ)。将使用Review Manager软件(5.3.5版)和R软件(3.6.1版)进行数据分析。将使用标准的Chi-Square试验评估统计异质性,其显着性水平为P <0.10。将使用漏斗图,EGGER的测试和BEGG测试和修剪和填充分析将研究与研究规模相关的偏差(例如,出版物偏见)。讨论本研究将提供高质量的中草药对Covid-19的影响。将研究使用中式中草药治疗或预防这些影响肺炎的新型病毒感染。系统审查登记Prospero注册号:

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号